Reply to “Using 18F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels”

2021 ◽  
Vol 216 (3) ◽  
pp. W11-W11
Author(s):  
Yingbing Wang ◽  
James A. Scott ◽  
Edwin L. Palmer
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Detect Prostate Cancer

Using 18F-Fluciclovine PET/CT to Detect Prostate Cancer Recurrence in Patients With Very Low PSA Levels

2021 ◽  
Vol 216 (3) ◽  
pp. W10-W10
Author(s):  
Barry A. Siegel ◽  
David M. Schuster ◽  
Bital Savir-Baruch
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Detect Prostate Cancer

Krebstherapie – 68Ga-PSMA-PET/CT beim rezidivierten Prostatakarzinom richtungweisend und kosteneffektiv

2020 ◽  
Vol 25 (04) ◽  
pp. 184-185
Author(s):  
Susanne Krome
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Intention To Treat ◽  
Biochemisches Rezidiv ◽  
Choline Pet ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Treat Analysis

Schwenck J et al. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. J Nucl Med 2019; 60: 1359–1365 15–40 % der Patienten mit einem Prostatakarzinom erleiden postoperativ ein biochemisches Rezidiv. In der retrospektiven Analyse beeinflussten die Bildgebungsverfahren die Häufigkeit einer richtigen Therapiewahl. Die Autoren empfehlen die 68Ga-PSMA-PET/CT, die die höchste Genauigkeit aufwies. Unter Berücksichtigung der Kosten für inadäquate Behandlungen entstünden keine ökonomischen Nachteile.

scholarly journals Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery

2019 ◽  
Vol 60 (10) ◽  
pp. 1359-1365 ◽  
Author(s):  
Johannes Schwenck ◽  
Susann-Cathrin Olthof ◽  
Christina Pfannenberg ◽  
Gerald Reischl ◽  
Daniel Wegener ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Intention To Treat ◽  
Choline Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Treat Analysis

Have we overcome choline PET/CT for early detection of prostate cancer recurrence?

2016 ◽  
Vol 37 (6) ◽  
pp. 567-569 ◽  
Author(s):  
Wolfgang P. Fendler ◽  
Christina Bluemel ◽  
Domenico Rubello ◽  
Ken Herrmann
Keyword(s):  
Prostate Cancer ◽  
Early Detection ◽  
Cancer Recurrence ◽  
Choline Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence

scholarly journals Establishing a Provincial Registry for Recurrent Prostate Cancer: Providing Access to PSMA PET/CT in Ontario, Canada

2021 ◽  
Vol 11 ◽  
Author(s):  
Sympascho Young ◽  
Ur Metser ◽  
Golmehr Sistani ◽  
Deanna L. Langer ◽  
Glenn Bauman
Keyword(s):  
Prostate Cancer ◽  
Imaging Modality ◽  
Cancer Recurrence ◽  
Steering Committee ◽  
Primary Therapy ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Health Canada ◽  
Pet Radiopharmaceuticals

Prostate Specific Membrane Antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is becoming established as a standard of care for the (re)staging of high-risk primary and prostate cancer recurrence after primary therapy. Despite the favorable performance of this imaging modality with high accuracy in disease detection, the availability of PSMA PET/CT varies across jurisdictions worldwide due to variability in the selection of PSMA PET/CT agent, regulatory approvals and funding. In Canada, PSMA based radiopharmaceuticals are still considered investigational new drug (IND), creating limitations in the deployment of these promising imaging agents. While regulatory approval rests with Health Canada, as a single payer health system, funding for Health Canada approved drugs and devices is decided by Provincial Health Ministries. Ontario Health (Cancer Care Ontario) (OH-CCO) is the agency of the Ministry of Health (MOH) in Ontario responsible for making recommendations to the MOH around the organization and funding of cancer services within Ontario (population of 15 million), and the PET Steering Committee of OH-CCO is responsible for providing recommendations on the introduction of new PET radiopharmaceuticals and indications. For Health Canada approved PET radiopharmaceuticals like 18F-FDG, OH-CCO (on behalf of the MOH) provides coverage based on levels of evidence and specific PET Registries are established to aid in real-world evidence collection to inform OH-CCO regarding emerging PET applications. In the case of PSMA PET/CT, adapting this model to an IND PSMA PET/CT agent, 18F-DCFPyL, necessitated the creation of a hybrid Registry-Study model to leverage the existing OH-CCO Registry structure while respecting the need for a Health Canada Clinical Trials Application (CTA) for the deployment of this agent in the province. Within the first 2 years of the registry, over 1700 men have been imaged resulting in a change in management (compared to pre-PET management plans) in over half of the men imaged. In this article, we describe the organization and deployment of the PSMA PET/CT (PREP) Registry throughout the province to provide access for men with suspected prostate cancer recurrence along with key stakeholder perspectives and preliminary results.

How does 68Ga-PSMA PET/CT impact the treatment management in patients with prostate cancer recurrence after surgery?

2019 ◽  
Vol 18 (1) ◽  
pp. e685-e686
Author(s):  
L. Bianchi ◽  
M. Borghesi ◽  
U. Barbaresi ◽  
F. Mineo Bianchi ◽  
P. Castellucci ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Treatment Management ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence

MP42-06 EARLY DETECTION OF PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY: THE ROLE OF 18F-CHOLINE PET/CT

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Giuseppe Simone ◽  
Giovanni Battista ◽  
Di Pierro ◽  
Carlo Ludovico Maini ◽  
Rocco Papalia ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Early Detection ◽  
Cancer Recurrence ◽  
Choline Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence

(68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy

2019 ◽  
Vol 23 (3) ◽  
pp. 194-200 ◽  
Author(s):  
B. De Bari ◽  
R. Mazzola ◽  
D. Aiello ◽  
D. Aloi ◽  
R. Gatta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cancer Recurrence ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence
Sign in / Sign up

Export Citation Format

Share Document